How to Get Tresiba in Minnesota: Prescriptions, Telehealth, and Pharmacy Access

What Tresiba Is and Why Clinicians Prescribe It

Insulin degludec is an ultra-long-acting basal insulin with a half-life exceeding 25 hours and a duration of action beyond 42 hours at steady state, making its glucose-lowering profile flatter than glargine U-100 or detemir. The FDA approved Tresiba in September 2015 for adults with type 1 or type 2 diabetes, and it is available in U-100 (FlexTouch 3 mL pen) and U-200 formulations.

The DEVOTE cardiovascular outcomes trial randomized 7,637 adults with type 2 diabetes at high cardiovascular risk to degludec or glargine U-100 over a median 2.0 years. Degludec was non-inferior for the primary MACE outcome (hazard ratio 0.91 to 95% CI 0.78 to 1.06) and produced a statistically significant 40% reduction in severe hypoglycemia (rate ratio 0.60 to 95% CI 0.48 to 0.76, P<0.001) [1]. That hypoglycemia advantage is the single most cited clinical reason Minnesota prescribers switch patients from older basal insulins to degludec.

The American Diabetes Association's 2024 Standards of Care note that "longer-acting insulin analogs (degludec, glargine U-300) are associated with less nocturnal hypoglycemia compared with NPH insulin or glargine U-100" [2]. For patients who experience nocturnal hypoglycemia on glargine or who require flexible injection timing because of shift work or irregular schedules, degludec is frequently the preferred agent.

Degludec's flat pharmacokinetic profile also means missing a dose by up to 8 hours does not produce the same glucose excursions seen with shorter-acting basal insulins [3]. That flexibility is clinically relevant for Minnesota patients in rural counties where pharmacy access or refrigeration may be intermittent.

Minnesota Telehealth Rules for Tresiba Prescriptions

Minnesota law permits telehealth prescribing of non-controlled prescription drugs, including all insulin formulations. A prescriber must hold an active Minnesota medical, nursing, or physician assistant license and must establish a valid patient-provider relationship before issuing a prescription. That relationship can be established via synchronous audio-video visit under Minnesota Statutes § 62A.673.

Insulin degludec is not a controlled substance under federal or Minnesota law, which means the Ryan Haight Act's in-person visit requirements do not apply. A licensed telehealth clinician can prescribe Tresiba after a qualifying video or phone visit, review of recent labs, and documentation of the clinical indication. The FDA's prescribing information requires no special Risk Evaluation and Mitigation Strategy (REMS) program for insulin degludec, simplifying the prescribing workflow compared with certain other specialty medications.

Telehealth platforms operating in Minnesota commonly request the following before writing a degludec prescription:

• Confirmed diagnosis of type 1 or type 2 diabetes (prior records, A1C, or fasting glucose)
• Current medication list, including any basal insulin already in use
• Fasting blood glucose log (at least 7 days preferred)
• Renal function panel if dose adjustment for eGFR is being considered
• Insurance card or self-pay preference to determine formulary pathway

Processing time at most telehealth practices is 24 to 72 hours from the completed visit to a pharmacy-ready prescription. A 2022 analysis in JAMA Internal Medicine found that telehealth visits for chronic disease management reduced median time to prescription receipt by 4.3 days compared with in-person scheduling in rural US counties [4], a figure directly relevant to patients in Greater Minnesota.

Who Can Prescribe Tresiba in Minnesota

Tresiba may be prescribed by any licensed Minnesota prescriber with authority to write prescriptions for non-controlled drugs. That group includes:

MDs and DOs. Physicians with an active Minnesota Board of Medical Practice license prescribe degludec routinely in primary care, endocrinology, and internal medicine settings.

Nurse Practitioners (NPs). Minnesota grants NPs full practice authority under Minn. Stat. § 148.235. An NP does not require physician supervision to prescribe Tresiba.

Physician Assistants (PAs). PAs in Minnesota operate under a delegation agreement with a supervising physician but may prescribe non-controlled medications including all insulin analogs. The Minnesota Board of Physician Assistant Practice oversees licensure.

Certified Diabetes Care and Education Specialists (CDCES). A CDCES who holds an independent prescriptive license (e.g., as an NP or PA) may prescribe degludec. A CDCES without a prescriptive license may adjust doses within a standing protocol signed by a supervising physician.

The American Association of Clinical Endocrinology (AACE) 2023 Comprehensive Diabetes Management Algorithm supports basal insulin initiation by any member of the care team who has received appropriate training, not exclusively by endocrinologists [5]. Primary care NPs and PAs in rural Minnesota counties therefore have full clinical and legal authority to prescribe and titrate Tresiba independently.

Labs and Clinical Workup Before Starting Tresiba

No unique pre-authorization laboratory panel is mandated by Tresiba's FDA label, but standard of care before starting any basal insulin includes baseline measurements that guide dosing and safety monitoring.

Hemoglobin A1C. Establishes glycemic control baseline. Most Minnesota insurers require a documented A1C for prior authorization. The ADA recommends an A1C target of <7% for most non-pregnant adults and <8% for those with significant hypoglycemia history or limited life expectancy [2].

Fasting plasma glucose. Used to calculate the starting dose and to set the titration target. Degludec titration algorithms published in clinical trials target a fasting glucose of 71 to 90 mg/dL (3.9 to 5.0 mmol/L) [1].

Basic metabolic panel (BMP). Renal function (eGFR, serum creatinine) informs insulin clearance expectations. Hepatic impairment may also affect insulin requirements. The FDA label notes that patients with renal or hepatic impairment may need more frequent glucose monitoring and dose adjustment [3].

Thyroid function (TSH). Not required by the label, but commonly ordered at diabetes initiation visits because thyroid dysfunction alters insulin sensitivity significantly.

Lipid panel. Relevant to overall cardiovascular risk stratification. Minnesota Medicaid prior authorization forms often request documentation of co-morbidities including dyslipidemia.

C-peptide and anti-GAD antibodies. Ordered when the type 1 vs. type 2 distinction is clinically uncertain, particularly in adults with LADA (latent autoimmune diabetes in adults). Misclassification of type 1 patients as type 2 can delay appropriate basal-bolus therapy.

A telehealth prescriber can order labs electronically to any LabCorp or Quest Diagnostics draw site in Minnesota. Results transmit to the provider portal within 24 to 48 hours for most standard panels, enabling a same-week prescription if the visit and labs are coordinated on the same day.

Prior Authorization Requirements for Tresiba in Minnesota

Minnesota Medicaid (Medical Assistance) covers insulin degludec for both type 1 and type 2 diabetes with prior authorization. Commercial plan requirements vary by payer but generally follow the same structural logic.

Step therapy documentation. Most Minnesota commercial plans and Medicaid require documentation that the patient has used NPH insulin or insulin glargine U-100 (Lantus/Basaglar) at an adequate dose for at least 90 days with suboptimal response, or that those agents are clinically contraindicated. "Suboptimal response" is typically defined as failure to achieve A1C <8% or recurrent hypoglycemia despite optimization.

Clinical rationale letter. A prescriber narrative explaining why degludec is medically necessary is almost universally required. Citing the DEVOTE trial data on severe hypoglycemia reduction [1] and the specific patient history (e.g., nocturnal hypoglycemia events documented in the chart) strengthens approval rates.

PA denial and appeals. If the initial PA is denied, Minnesota law gives patients the right to an expedited appeal within 72 hours for urgent medical needs and a standard appeal within 30 days. The prescriber may submit additional documentation including peer-reviewed literature. Endocrine Society clinical practice guidelines support the use of longer-acting analogs in patients with hypoglycemia unawareness [6], and that citation can be included in appeal letters.

Bridge supply. While PA is pending, many prescribers write a 30-day cash-pay or manufacturer coupon-covered supply. Novo Nordisk's patient assistance program (NovoCare) provides Tresiba at no cost to qualifying uninsured or underinsured Minnesota residents who meet income criteria.

Minnesota Pharmacy Access: Retail, Mail-Order, and 503A Options

Retail chains. Tresiba FlexTouch pens are stocked or can be ordered within 24 to 48 hours at major Minnesota retail pharmacy chains including CVS, Walgreens, Hy-Vee Pharmacy, and most Coborn's locations. Independent pharmacies in smaller towns may require 1 to 3 business days for special order.

Mail-order pharmacies. OptumRx, CVS Caremark, and Express Scripts all ship insulin degludec to Minnesota addresses with cold-pack packaging. Standard shipping is 5 to 7 business days from prescription receipt; expedited options reduce that to 2 to 3 business days. Insulin requires refrigeration at 36°F to 46°F (2°C to 8°C) until first use; after opening, the pen may be kept at room temperature below 86°F (30°C) for up to 56 days per the prescribing information [3].

503A compounding pharmacies. Licensed 503A compounding pharmacies in Minnesota may prepare patient-specific insulin formulations under a valid prescription when a commercially manufactured product is unavailable or clinically inappropriate for the individual patient. The FDA distinguishes 503A pharmacies (patient-specific) from 503B outsourcing facilities (batch production). Minnesota Board of Pharmacy records confirm several 503A-licensed pharmacies operating in the Twin Cities metro and Duluth areas. Because commercial Tresiba is FDA-approved and generally available, 503A compounding of insulin degludec is less common than for other peptides; the primary use case is custom concentration preparations for patients with significant insulin resistance requiring volumes impractical with commercial pens.

Cost without insurance. The list price of Tresiba FlexTouch (5 pens, 3 mL each, U-100) is approximately $530 per box. GoodRx coupons reduce this to roughly $280 to $340 at Minnesota pharmacies depending on location. Novo Nordisk's My$99Insulin program caps the monthly cost at $99 for eligible patients regardless of dose. The Inflation Reduction Act insulin pricing cap of $35/month applies to Medicare Part D beneficiaries effective January 2023 [7].

Transferring an Existing Tresiba Prescription to Minnesota

Patients relocating to Minnesota or establishing care with a new in-state provider may transfer a Tresiba prescription under the following framework:

A retail pharmacy transfer is straightforward: any Minnesota-licensed pharmacy can receive a transfer from another state's retail pharmacy for a non-controlled drug. The receiving pharmacist contacts the originating pharmacy directly. One transfer per prescription is allowed under most state pharmacy rules, after which a new prescription from a Minnesota-licensed prescriber is required.

Patients with mail-order prescriptions through a national PBM (pharmacy benefit manager) may update their ship-to address to a Minnesota address without changing the prescribing physician, as long as the mail-order pharmacy holds a Minnesota non-resident pharmacy license. All three major mail-order pharmacies noted above hold valid Minnesota licenses per Board of Pharmacy records.

If the original prescriber is not licensed in Minnesota, a new prescription from a Minnesota-licensed provider is mandatory. A telehealth visit with a Minnesota-licensed clinician resolves this in 24 to 72 hours for most patients.

Dosing and Titration Protocols Clinicians Use in Minnesota

The FDA-approved starting dose for type 2 diabetes naive to insulin is 10 units subcutaneously once daily [3]. For type 1 diabetes, degludec replaces the existing basal insulin at the same unit dose, with subsequent titration based on fasting glucose response.

The standard titration algorithm from the BEGIN trials titrates by 2 units every 3 days when the mean fasting self-monitored blood glucose over 3 consecutive days exceeds 90 mg/dL, targeting 71 to 90 mg/dL [8]. A more aggressive algorithm titrates by 4 units every 3 days; that protocol was associated with faster time to target without a significant increase in hypoglycemia in a 2019 study published in Diabetes Care (N=458) [8].

Degludec can be injected at any time of day, with the only requirement being that consecutive injections be at least 8 hours apart. This dosing flexibility distinguishes it from glargine U-300 (Toujeo), which is also available in Minnesota but carries a fixed once-daily recommendation without the same flexibility window. Clinical practice in Minnesota endocrinology offices frequently uses this feature to accommodate patients who work overnight shifts at facilities including the large manufacturing and healthcare employers in the Twin Cities metro.

Maximum approved dose is not specified in the label; dose is individualized. However, patients requiring more than 200 units per day in the U-100 formulation should be considered for the U-200 Tresiba pen, which delivers the same number of units in half the injection volume.

Monitoring After Starting Tresiba in Minnesota

After initiating or titrating degludec, standard monitoring includes:

Self-monitored fasting blood glucose (SMBG). Daily fasting readings guide titration. Minnesota Medicaid covers blood glucose meters and strips under the Durable Medical Equipment benefit for qualifying patients with diabetes who use insulin [9].

A1C rechecked at 3 months. The ADA recommends A1C testing every 3 months until target is reached, then every 6 months once stable [2]. Most telehealth platforms integrated with Minnesota lab networks automate the follow-up order at the time of the initial prescription.

Hypoglycemia documentation. Any severe hypoglycemia event (requiring third-party assistance) should be documented and may trigger a clinical review of the titration target or concomitant medications, including sulfonylureas or other insulin secretagogues that potentiate hypoglycemia risk when combined with basal insulin.

Injection site rotation. Degludec is injected into the abdomen, thigh, or upper arm. Lipohypertrophy at injection sites alters absorption unpredictably; a 2023 study in Diabetes Technology and Therapeutics found that lipohypertrophy affected insulin absorption in 39.1% of insulin users who had not received formal rotation instruction [10].

Annual kidney function panel. Progressive diabetic nephropathy changes insulin clearance and lowers the dose needed to avoid hypoglycemia. eGFR trending below 30 mL/min/1.73m² typically warrants dose reduction and increased SMBG frequency.